15210-64-7

Usage

Uses

Used in Pharmaceutical Industry:
N-acetyl-3,5,7-trimethyl-1-aminoadamantane is used as an intermediate in the synthesis of Memantine (HCl salt, M218000) for its antiparkinsonian and antispasmodic properties. Memantine is a medication primarily used to treat Parkinson's disease and various spastic conditions by acting on the central nervous system and providing relief from symptoms.
In the synthesis process, N-acetyl-3,5,7-trimethyl-1-aminoadamantane plays a vital role in the formation of Memantine, which is the active pharmaceutical ingredient in the final drug product. The compound's unique structure and properties make it an essential component in the development of medications targeting neurological disorders and muscle spasms.

Upstream product

• 53398-55-3 1-bromo-3,5,7-trimethyladamantane 
• 75-05-8 acetonitrile 
• 101821-78-7 1,3,5-Trimethyl-7-nitrooxy-adamantane 
• 60-35-5 acetamide 
• 707-35-7 1,3,5-trimethyladamantane 
• 50741-88-3 1,3,5-trimethyl-7-adamantane carbonyl chloride 
• 24666-21-5 methyl 3,5,7-trimethyl-1-adamantyl ketone 
• 84880-08-0 methyl 3,5,7-trimethyl-1-adamantyl ketone oxime 
• 84880-09-1 methyl 3,5,7-trimethyl-1-adamantyl ketone O-trimethylsilyloxime 

Downstream Products

• 15291-66-4 3,5,7-trimethyladamantanecarboxylic acid 
• 15210-60-3 3,5,7-trimethyl-1-aminoadamantane hydrochloride 

Relevant academic research and scientific papers

Synthesis of Cage Acylamino Derivatives in Nitric Acid Medium

Abstract: An efficient procedure has been developed for the synthesis of secondary amides by the Ritter reaction of cage substrates with a wide series of nitriles in fuming nitric acid and its mixtures.

PROCESS FOR PREPARING MEMANTINE HYDROCHLORIDE SUBSTANTIALLY FREE OF IMPURITIES

The present invention encompasses processes for preparing Memantine hydrochloride and its derivatives, substantially free of impurities.

Structure-Anti-Parkinson Activity Relationships in the Aminoadamantanes. Influence of Bridgehead Substitution

A limited series of bridgehead alkyl-, dialkyl- and trialkyl-substituted amantadines was synthesized and tested for potential anti-Parkinson activity as dopamine (DA) agonists.The compounds were evaluated using a battery of three murine bioassays, including stimulation of locomotor activity, induction of circling in animals with unilateral striatal lesions, and reversal of reserpine/α-methyltyrosine induced akinesia.Apparent mechanistic differences were seen between the methyl-substituted series and the ethyl-substituted series.While activities in both series increase with increasing liphophilicity, the methyl series (1b-d), as well as amantadine itself (1a) exhibits only indirect DA agonist activity, as evidenced by ipsilateral rotation in the circling model and no significant difference from control in reversal of akinesia.The ethyl series (1e,f) exhibits weak but reprodicible direct DA agonist activity, as shown by contralateral rotation in the circling assay for 1e and reversal of akinesia by 1e and 1f.The 3-n-propyl derivative (1g) was devoid of any DA agonist activity.